{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:52:47Z","timestamp":1793994767709,"version":"4.8.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ever Pharma","award":["no number"],"award-info":[{"award-number":["no number"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) affects approximately 1% of individuals over the age of 60, with its prevalence increasing in older populations. Clinical manifestations can be effectively controlled during the first years of disease but progressively medications effect shortens with appearance of motor complications and dyskinesia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Areas covered<\/jats:title>\n                    <jats:p>Management of PD primarily aims to restore dopaminergic activity through pharmacological interventions such as levodopa, which effectively alleviates motor symptoms and extends life expectancy. Early initiation of treatment improves bradykinesia, rigidity, and tremor; however, as the disease advances, the therapeutic response to levodopa shortens, leading to complications such as motor fluctuations and dyskinesia. In advanced Parkinson\u2019s disease (aPD), the emergence of the \u201cwearing-off\u201d phenomenon and unpredictable \u201con\/off\u201d fluctuations\u2014where symptoms reappear despite medications\u2014poses significant challenges for disease management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Expert opinion<\/jats:title>\n                    <jats:p>Device-aided therapies, including deep brain stimulation and continuous infusion of apomorphine or levodopa, provide effective management options for advanced Parkinson\u2019s disease (aPD) when oral medications fail to adequately control symptoms. Continuous subcutaneous apomorphine infusion (CSAI) has demonstrated both efficacy and long-term tolerability; however, its clinical adoption remains limited due to challenges in patient selection and referral, treatment initiation and handling of the device. This review examines the available infusion therapies, with a particular focus on CSAI, and aims to provide clinicians with evidence-based guidance for optimizing treatment selection in aPD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-026-09228-5","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:47:27Z","timestamp":1784098047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Device aided therapies in Parkinson disease: an expert view on apomorphine"],"prefix":"10.1007","volume":"47","author":[{"given":"Fabrizio","family":"Stocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ceravolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"De Pandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Modugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Pilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tessitore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Tinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Valzania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zangaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Zappia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zibetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"9228_CR1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00702-018-1906-0","volume":"125","author":"A Antonini","year":"2018","unstructured":"Antonini A, Nitu B (2018) Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J Neural Transm 125:1131\u20131135. https:\/\/doi.org\/10.1007\/s00702-018-1906-0","journal-title":"J Neural Transm"},{"key":"9228_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00415-010-5793-z","volume":"258","author":"A Antonini","year":"2011","unstructured":"Antonini A, Isaias IU, Rodolfi G, Landi A, Natuzzi F, Siri C, Pezzoli G (2011) A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 258:579\u2013585. https:\/\/doi.org\/10.1007\/s00415-010-5793-z","journal-title":"J Neurol"},{"key":"9228_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2165\/11310940-000000000-00000","volume":"24","author":"A Antonini","year":"2010","unstructured":"Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P (2010) Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson\u02bcs disease. CNS Drugs 24:119\u2013129. https:\/\/doi.org\/10.2165\/11310940-000000000-00000","journal-title":"CNS Drugs"},{"key":"9228_CR4","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, \u015ami\u0142owska K, Berg D, Corvol J, Fabbrini G, Ferreira J, Foltynie T, Mir P et al (2022) European Academy of Neurology\/Movement Disorder Society\u2010European Section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies. Mov Disord 37:1360\u20131374. https:\/\/doi.org\/10.1002\/mds.29066","journal-title":"Mov Disord"},{"key":"9228_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","volume":"66","author":"R Pahwa","year":"2006","unstructured":"Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ (2006) Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): [RETIRED]. Neurology 66:983\u2013995. https:\/\/doi.org\/10.1212\/01.wnl.0000215250.82576.87","journal-title":"Neurology"},{"key":"9228_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4047392","volume":"2017","author":"M-R Luquin","year":"2017","unstructured":"Luquin M-R, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES (2017) Consensus on the definition of advanced Parkinson\u2019s disease: a neurologists-based Delphi study (CEPA study). Parkinsons Dis 2017:1\u20138. https:\/\/doi.org\/10.1155\/2017\/4047392","journal-title":"Parkinsons Dis"},{"key":"9228_CR7","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"key":"9228_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.parkreldis.2013.10.027","volume":"20","author":"F Stocchi","year":"2014","unstructured":"Stocchi F, Antonini A, Barone P, Tinazzi M, Zappia M, Onofrj M, Ruggieri S, Morgante L, Bonuccelli U, Lopiano L et al (2014) Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 20:204\u2013211. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.10.027","journal-title":"Parkinsonism Relat Disord"},{"key":"9228_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/mds.25898","volume":"29","author":"AD Macleod","year":"2014","unstructured":"Macleod AD, Taylor KSM, Counsell CE (2014) Mortality in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 29:1615\u20131622. https:\/\/doi.org\/10.1002\/mds.25898","journal-title":"Mov Disord"},{"key":"9228_CR10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","volume":"80","author":"RA Hauser","year":"2023","unstructured":"Hauser RA, Espay AJ, Ellenbogen AL, Fernandez HH, Isaacson SH, LeWitt PA, Ondo WG, Pahwa R, Schwarz J, Stocchi F et al (2023) IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease. JAMA Neurol 80:1062. https:\/\/doi.org\/10.1001\/jamaneurol.2023.2679","journal-title":"JAMA Neurol"},{"key":"9228_CR11","doi-asserted-by":"publisher","first-page":"1301240","DOI":"10.3389\/fneur.2023.1301240","volume":"14","author":"X Tian","year":"2023","unstructured":"Tian X, Hu R, He P, Ye J (2023) Efficacy and safety of magnetic resonance-guided focused ultrasound for Parkinson\u2019s disease: a systematic review and meta-analysis. Front Neurol 14:1301240. https:\/\/doi.org\/10.3389\/fneur.2023.1301240","journal-title":"Front Neurol"},{"key":"9228_CR12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40263-022-00963-9","volume":"36","author":"A Antonini","year":"2022","unstructured":"Antonini A, Pahwa R, Odin P, Isaacson SH, Merola A, Wang L, Kandukuri PL, Alobaidi A, Yan CH, Bao Y et al (2022) Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis. CNS Drugs 36:1269\u20131283. https:\/\/doi.org\/10.1007\/s40263-022-00963-9","journal-title":"CNS Drugs"},{"key":"9228_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism. Neurology 17:427\u2013427. https:\/\/doi.org\/10.1212\/WNL.17.5.427","journal-title":"Neurology"},{"key":"9228_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/1874205X01206010037","volume":"6","author":"PS Worlich","year":"2012","unstructured":"Worlich PS (2012) Practical Guidance on How to Handle Levodopa\/Carbidopa Intestinal Gel Therapy of Advanced PD in a Movement Disorder Clinic. Open Neurol J 6:37\u201350. https:\/\/doi.org\/10.2174\/1874205X01206010037","journal-title":"Open Neurol J"},{"issue":"1","key":"9228_CR15","doi-asserted-by":"publisher","first-page":"e70024","DOI":"10.1111\/ene.70024","volume":"32","author":"K Smilowska","year":"2025","unstructured":"Smilowska K, Carvalho V, Szejko N, Costa J, Moro E, Antonini A (2025) How well is the female population represented in clinical trials with infusion therapies for Parkinson\u2019s disease? A systematic review and metanalysis. Eur J Neurol 32(1):e70024. https:\/\/doi.org\/10.1111\/ene.70024","journal-title":"Eur J Neurol"},{"key":"9228_CR16","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","volume":"80","author":"RA Hauser","year":"2023","unstructured":"Hauser RA, Espay AJ, Ellenbogen AL, Fernandez HH, Isaacson SH, LeWitt PA, Ondo WG, Pahwa R, Schwarz J, Stocchi F et al (2023) IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease. JAMA Neurol 80:1062. https:\/\/doi.org\/10.1001\/jamaneurol.2023.2679","journal-title":"JAMA Neurol"},{"key":"9228_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","volume":"21","author":"P Mart\u00ednez-Mart\u00edn","year":"2015","unstructured":"Mart\u00ednez-Mart\u00edn P, Rodr\u00edguez-Bl\u00e1zquez C, Alvarez Mario, Arakaki T, Arillo VC, Chan\u00e1 P, Fern\u00e1ndez W, Garretto N, Mart\u00ednez-Castrillo JC, Rodr\u00edguez-Violante M et al (2015) Parkinson\u2019s disease severity levels and MDS-Unified Parkinson\u2019s Disease Rating Scale. Parkinsonism Relat Disord 21:50\u201354. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.10.026","journal-title":"Parkinsonism Relat Disord"},{"key":"9228_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/ene.13529","volume":"25","author":"F Stocchi","year":"2018","unstructured":"Stocchi F, Radicati FG, Chaudhuri KR, Johansson A, Padmakumar C, Falup-Pecurariu C, Martinez-Martin P (2018) The Parkinson\u2019s Disease Composite Scale: results of the first validation study. Eur J Neurol 25:503\u2013511. https:\/\/doi.org\/10.1111\/ene.13529","journal-title":"Eur J Neurol"},{"key":"9228_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/mds.27216","volume":"33","author":"CW Olanow","year":"2018","unstructured":"Olanow CW, Stocchi F (2018) Levodopa: a new look at an old friend. Mov Disord 33:859\u2013866. https:\/\/doi.org\/10.1002\/mds.27216","journal-title":"Mov Disord"},{"key":"9228_CR20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim S, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C (2018) International Parkinson and movement disorder society evidence\u2010based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 33:1248\u20131266. https:\/\/doi.org\/10.1002\/mds.27372","journal-title":"Mov Disord"},{"key":"9228_CR21","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/mds.28215","volume":"35","author":"CW Olanow","year":"2020","unstructured":"Olanow CW, Calabresi P, Obeso JA (2020) Continuous dopaminergic stimulation as a treatment for Parkinson\u2019s disease: current status and future opportunities. Mov Disord 35:1731\u20131744. https:\/\/doi.org\/10.1002\/mds.28215","journal-title":"Mov Disord"},{"key":"9228_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol 5:677\u2013687. https:\/\/doi.org\/10.1016\/S1474-4422(06)70521-X","journal-title":"Lancet Neurol"},{"key":"9228_CR23","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/mds.29028","volume":"37","author":"K Kolman\u010di\u010d","year":"2022","unstructured":"Kolman\u010di\u010d K, Zupan\u010di\u010d NK, Tro\u0161t M, Flisar D, Kramberger MG, Pirto\u0161ek Z, Kojovi\u0107 M (2022) Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson\u2019s Disease. Mov Disord 37:1465\u20131473. https:\/\/doi.org\/10.1002\/mds.29028","journal-title":"Mov Disord"},{"key":"9228_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ana.410230611","volume":"23","author":"R Kurlan","year":"1988","unstructured":"Kurlan R, Nutt JG, Woodward WR, Rothfield K, Lichter D, Miller C, Carter JH, Shoulson I (1988) Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 23:589\u2013595. https:\/\/doi.org\/10.1002\/ana.410230611","journal-title":"Ann Neurol"},{"key":"9228_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0140-6736(89)90285-7","volume":"334","author":"S Ruggieri","year":"1989","unstructured":"Ruggieri S, Stocchi F, Carta A, Catarci M, Agnoli A (1989) Jejunal delivery of levodopa methyl ester. Lancet 334:45\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(89)90285-7","journal-title":"Lancet"},{"key":"9228_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/jnnp-2016-314500","volume":"89","author":"AL Ho","year":"2018","unstructured":"Ho AL, Ali R, Connolly ID, Henderson JM, Dhall R, Stein SC, Halpern CH (2018) Awake versus asleep deep brain stimulation for Parkinson\u2019s disease: a critical comparison and meta-analysis. J Neurol Neurosurg Psychiatry 89:687\u2013691. https:\/\/doi.org\/10.1136\/jnnp-2016-314500","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9228_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1124\/jpet.114.216317","volume":"351","author":"SMR Camargo","year":"2014","unstructured":"Camargo SMR, Vuille-dit-Bille RN, Mariotta L, Ramadan T, Huggel K, Singer D, G\u00f6tze O, Verrey F (2014) The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson\u2019s disease. J Pharmacol Exp Ther 351:114\u2013123. https:\/\/doi.org\/10.1124\/jpet.114.216317","journal-title":"J Pharmacol Exp Ther"},{"key":"9228_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/mdc3.12630","volume":"5","author":"M Burack","year":"2018","unstructured":"Burack M, Aldred J, Zadikoff C, Vanagunas A, Klos K, Bilir B, Fernandez HH, Standaert DG (2018) Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners. Mov Disord Clin Pract 5:383\u2013393. https:\/\/doi.org\/10.1002\/mdc3.12630","journal-title":"Mov Disord Clin Pract"},{"issue":"6","key":"9228_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/archneur.62.6.905","volume":"62","author":"F Stocchi","year":"2005","unstructured":"Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease. Arch Neurol 62(6):905\u201310. https:\/\/doi.org\/10.1001\/archneur.62.6.905","journal-title":"Arch Neurol"},{"key":"9228_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","volume":"64","author":"D Nyholm","year":"2005","unstructured":"Nyholm D, Nilsson Remahl AIM, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius S-M, Askmark H (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216\u2013223. https:\/\/doi.org\/10.1212\/01.WNL.0000149637.70961.4C","journal-title":"Neurology"},{"key":"9228_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141\u2013149. https:\/\/doi.org\/10.1016\/S1474-4422(13)70293-X","journal-title":"Lancet Neurol"},{"key":"9228_CR32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VSC, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Mov Disord 30:500\u2013509. https:\/\/doi.org\/10.1002\/mds.26123","journal-title":"Mov Disord"},{"key":"9228_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/JPD-140456","volume":"5","author":"JT Slevin","year":"2015","unstructured":"Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, Chatamra K, Benesh J (2015) Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson\u2019s disease patients. J Parkinsons Dis 5:165\u2013174. https:\/\/doi.org\/10.3233\/JPD-140456","journal-title":"J Parkinsons Dis"},{"key":"9228_CR34","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.27338","volume":"33","author":"HH Fernandez","year":"2018","unstructured":"Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K et al (2018) Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease. Mov Disord 33:928\u2013936. https:\/\/doi.org\/10.1002\/mds.27338","journal-title":"Mov Disord"},{"key":"9228_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirto\u0161ek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L et al (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13\u201320. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.018","journal-title":"Parkinsonism Relat Disord"},{"key":"9228_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000346762","volume":"69","author":"P Taba","year":"2013","unstructured":"Taba P, Lees A, Stern G (2013) Erich Harnack (1852\u20131915) and a short history of apomorphine. Eur Neurol 69:321\u2013324. https:\/\/doi.org\/10.1159\/000346762","journal-title":"Eur Neurol"},{"key":"9228_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40261-018-0619-3","volume":"38","author":"M Auffret","year":"2018","unstructured":"Auffret M, Drapier S, V\u00e9rin M (2018) Pharmacological insights into the use of apomorphine in Parkinson\u2019s disease: clinical relevance. Clin Drug Investig 38:287\u2013312. https:\/\/doi.org\/10.1007\/s40261-018-0619-3","journal-title":"Clin Drug Investig"},{"key":"9228_CR38","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.parkreldis.2016.12.003","volume":"33","author":"P Jenner","year":"2016","unstructured":"Jenner P, Katzenschlager R (2016) Apomorphine - pharmacological properties and clinical trials in Parkinson\u2019s disease. Parkinsonism Relat Disord 33:S13\u2013S21. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.12.003","journal-title":"Parkinsonism Relat Disord"},{"key":"9228_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/WNF.0000000000000111","volume":"38","author":"M Nomoto","year":"2015","unstructured":"Nomoto M, Kubo S, Nagai M, Yamada T, Tamaoka A, Tsuboi Y, Hattori N (2015) A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease. Clin Neuropharmacol 38:241\u2013247. https:\/\/doi.org\/10.1097\/WNF.0000000000000111","journal-title":"Clin Neuropharmacol"},{"key":"9228_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/mdc3.12350","volume":"4","author":"S Isaacson","year":"2017","unstructured":"Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F (2017) Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson\u2019s disease. Mov Disord Clin Pract 4:78\u201383. https:\/\/doi.org\/10.1002\/mdc3.12350","journal-title":"Mov Disord Clin Pract"},{"key":"9228_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/WNF.0b013e31816d91f9","volume":"32","author":"PA LeWitt","year":"2009","unstructured":"LeWitt PA, Ondo WG, Van Lunen B, Bottini PB (2009) Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating \u201coff\u201d episodes in advanced Parkinson disease. Clin Neuropharmacol 32:89\u201393. https:\/\/doi.org\/10.1097\/WNF.0b013e31816d91f9","journal-title":"Clin Neuropharmacol"},{"key":"9228_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00002826-199304000-00003","volume":"16","author":"CL Gervason","year":"1993","unstructured":"Gervason CL, Pollak PR, Limousin P, Ferret JE (1993) Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson\u02bcs disease. Clin Neuropharmacol 16:113\u2013119. https:\/\/doi.org\/10.1097\/00002826-199304000-00003","journal-title":"Clin Neuropharmacol"},{"key":"9228_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00415-019-09184-5","volume":"266","author":"\u00c1 Sesar","year":"2019","unstructured":"Sesar \u00c1, Fern\u00e1ndez-Pajar\u00edn G, Ares B, Relova J-L, Ar\u00e1n E, Rivas M-T, Gelabert-Gonz\u00e1lez M, Castro A (2019) Continuous subcutaneous apomorphine in advanced Parkinson\u2019s disease patients treated with deep brain stimulation. J Neurol 266:659\u2013666. https:\/\/doi.org\/10.1007\/s00415-019-09184-5","journal-title":"J Neurol"},{"key":"9228_CR44","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","volume":"21","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder C, Chaudhuri KR, Garc\u00eda Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-D\u00f6ring F, Henriksen T, Sesar \u00c1, Poewe W, Baker M et al (2015) Expert consensus group report on the use of apomorphine in the treatment of Parkinson\u2019s disease \u2013 clinical practice recommendations. Parkinsonism Relat Disord 21:1023\u20131030. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.06.012","journal-title":"Parkinsonism Relat Disord"},{"key":"9228_CR45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749\u2013759. https:\/\/doi.org\/10.1016\/S1474-4422(18)30239-4","journal-title":"Lancet Neurol"},{"key":"9228_CR46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.33588\/rn.7908.2024117","volume":"79","author":"C Garc\u00eda Fern\u00e1ndez","year":"2024","unstructured":"Garc\u00eda Fern\u00e1ndez C, Vargas Mendoza AK, L\u00f3pez L\u00f3pez B, Bl\u00e1zquez Estrada M, Su\u00e1rez San Mart\u00edn ME (2024) Uso de infusi\u00f3n subcut\u00e1nea continua nocturna de apomorfina en la enfermedad de Parkinson avanzada: una serie de 37 casos. Rev Neurol 79:217. https:\/\/doi.org\/10.33588\/rn.7908.2024117","journal-title":"Rev Neurol"},{"key":"9228_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3233\/JPD-202285","volume":"11","author":"CW Olanow","year":"2021","unstructured":"Olanow CW, Espay AJ, Stocchi F, Ellenbogen AL, Leinonen M, Adar L, Case RJ, Orenbach SF, Yardeni T, Oren S et al (2021) Continuous subcutaneous levodopa delivery for Parkinson\u2019s disease: a randomized study. J Parkinsons Dis 11:177\u2013186. https:\/\/doi.org\/10.3233\/JPD-202285","journal-title":"J Parkinsons Dis"},{"key":"9228_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107293","volume":"132","author":"AL Ellenbogen","year":"2025","unstructured":"Ellenbogen AL, Poewe W, Espay AJ, Simuni T, Gurevich T, Yardeni T, Lopes N, Sasson N, Case R, Stocchi F et al (2025) Long-term, continuous, subcutaneous levodopa\/carbidopa infusion with ND0612 in Parkinson\u2019s disease: 3-year outcomes from the open-label BeyoND study. Parkinsonism Relat Disord 132:107293. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107293","journal-title":"Parkinsonism Relat Disord"},{"key":"9228_CR49","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.parkreldis.2022.03.012","volume":"97","author":"M Rosebraugh","year":"2022","unstructured":"Rosebraugh M, Stodtmann S, Liu W, Facheris MF (2022) Foslevodopa\/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Parkinsonism Relat Disord 97:68\u201372. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.03.012","journal-title":"Parkinsonism Relat Disord"},{"key":"9228_CR50","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ana.26073","volume":"90","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Voight EA, Moussa EM, Jameel F, Lou X, Zhang GGZ, Mayer PT, Stolarik D, Carr RA, Enright BP et al (2021) Foslevodopa\/Foscarbidopa: a new subcutaneous treatment for Parkinson\u2019s disease. Ann Neurol 90:52\u201361. https:\/\/doi.org\/10.1002\/ana.26073","journal-title":"Ann Neurol"},{"key":"9228_CR51","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O\u2019Neill D et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099\u20131109. https:\/\/doi.org\/10.1016\/S1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"key":"9228_CR52","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1002\/mds.28758","volume":"36","author":"W Poewe","year":"2021","unstructured":"Poewe W, Stocchi F, Arkadir D, Ebersbach G, Ellenbogen AL, Giladi N, Isaacson SH, Kieburtz K, LeWitt P, Olanow CW et al (2021) Subcutaneous Levodopa Infusion for Parkinson\u2019s Disease: 1-Year Data from the Open-Label BeyoND Study. Mov Disord 36:2687\u20132692. https:\/\/doi.org\/10.1002\/mds.28758","journal-title":"Mov Disord"},{"key":"9228_CR53","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1021\/acs.joc.1c00905","volume":"87","author":"AD Huters","year":"2022","unstructured":"Huters AD, Stambuli J, Klix RC, Matulenko MA, Chan VS, Simanis J, Hill DR, Reddy RE, Towne TB, Bellettini JR et al (2022) Scalable asymmetric syntheses of foslevodopa and foscarbidopa drug substances for the treatment of Parkinson\u2019s disease. J Org Chem 87:1986\u20131995. https:\/\/doi.org\/10.1021\/acs.joc.1c00905","journal-title":"J Org Chem"},{"key":"9228_CR54","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3233\/JPD-212813","volume":"11","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Liu W, Neenan M, Facheris MF (2021) Foslevodopa\/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Parkinsons Dis 11:1695\u20131702. https:\/\/doi.org\/10.3233\/JPD-212813","journal-title":"J Parkinsons Dis"},{"key":"9228_CR55","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR et al (2023) Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12:1937\u20131958. https:\/\/doi.org\/10.1007\/s40120-023-00533-1","journal-title":"Neurol Ther"},{"key":"9228_CR56","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/17434440.2025.2499153","volume":"22","author":"K Pop\u0142awska-Domaszewicz","year":"2025","unstructured":"Pop\u0142awska-Domaszewicz K, Metta V, Odin P, Chaudhuri KR (2025) The device-aided intrajejunal delivery of levodopa\u2013entacapone\u2013carbidopa intestinal gel the treatment of Parkinson\u2019s disease: overview of efficacy and safety. Expert Rev Med Devices 22:533\u2013544. https:\/\/doi.org\/10.1080\/17434440.2025.2499153","journal-title":"Expert Rev Med Devices"},{"key":"9228_CR57","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/jpm11040254","volume":"11","author":"M \u00d6thman","year":"2021","unstructured":"\u00d6thman M, Widman E, Nygren I, Nyholm D (2021) Initial experience of the levodopa\u2013entacapone\u2013carbidopa intestinal gel in clinical practice. J Pers Med 11:254. https:\/\/doi.org\/10.3390\/jpm11040254","journal-title":"J Pers Med"},{"key":"9228_CR58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.26855","volume":"32","author":"M Senek","year":"2017","unstructured":"Senek M, Nielsen EI, Nyholm D (2017) Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: a randomized crossover study. Mov Disord 32:283\u2013286. https:\/\/doi.org\/10.1002\/mds.26855","journal-title":"Mov Disord"},{"key":"9228_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70046","author":"D Weiss","year":"2025","unstructured":"Weiss D, Jost WH, Sz\u00e1sz JA, Pirto\u0161ek Z, Milanov I, Tomantschger V, Kov\u00e1cs N, Staines H, Amlani B, Smith N et al (2025) Levodopa\u2013Entacapone\u2013Carbidopa Intrajejunal Infusion in Advanced Parkinson\u2019s Disease \u2013 Interim Analysis of the ELEGANCE Study. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70046","journal-title":"Mov Disord Clin Pract"},{"key":"9228_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2408","author":"KAM Pauls","year":"2021","unstructured":"Pauls KAM, Toppila J, Koivu M, Eerola\u2010Rautio J, Udd M, Pekkonen E (2021) Polyneuropathy monitoring in Parkinson\u2019s disease patients treated with levodopa\/carbidopa intestinal gel. Brain Behav. https:\/\/doi.org\/10.1002\/brb3.2408","journal-title":"Brain Behav"},{"key":"9228_CR61","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2165\/00002512-200421110-00001","volume":"21","author":"D Deleu","year":"2004","unstructured":"Deleu D, Hanssens Y, Northway MG (2004) Subcutaneous apomorphine. Drugs Aging 21:687\u2013709. https:\/\/doi.org\/10.2165\/00002512-200421110-00001","journal-title":"Drugs Aging"},{"key":"9228_CR62","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41582-018-0083-y","volume":"14","author":"A Antonini","year":"2018","unstructured":"Antonini A, Jenner P (2018) Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol 14:693\u2013694. https:\/\/doi.org\/10.1038\/s41582-018-0083-y","journal-title":"Nat Rev Neurol"},{"key":"9228_CR63","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.parkreldis.2016.11.020","volume":"33","author":"M Rosa-Grilo","year":"2016","unstructured":"Rosa-Grilo M, Qamar MA, Evans A, Chaudhuri KR (2016) The efficacy of apomorphine \u2013 a non-motor perspective. Parkinsonism Relat Disord 33:S28\u2013S35. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.020","journal-title":"Parkinsonism Relat Disord"},{"key":"9228_CR64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/mdc3.12373","volume":"4","author":"B Venegas P\u00e9rez","year":"2017","unstructured":"Venegas P\u00e9rez B, Arquero Portero T, S\u00e1nchez Fern\u00e1ndez MS, Feliz Feliz C, del Val Fern\u00e1ndez J, Garc\u00eda\u2010Ruiz PJ (2017) Apomorphine\u2010induced immune hemolytic anemia. Mov Disord Clin Pract 4:145\u2013147. https:\/\/doi.org\/10.1002\/mdc3.12373","journal-title":"Mov Disord Clin Pract"},{"key":"9228_CR65","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/bcp.12964","volume":"82","author":"C Renoux","year":"2016","unstructured":"Renoux C, Dell\u2019Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R et al (2016) Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson\u2019s disease. Br J Clin Pharmacol 82:461\u2013472. https:\/\/doi.org\/10.1111\/bcp.12964","journal-title":"Br J Clin Pharmacol"},{"key":"9228_CR66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/WNF.0000000000000082","volume":"38","author":"R Bhidayasiri","year":"2015","unstructured":"Bhidayasiri R, Chaudhuri KR, LeWitt P, Martin A, Boonpang K, van Laar T (2015) Effective delivery of apomorphine in the management of Parkinson disease. Clin Neuropharmacol 38:89\u2013103. https:\/\/doi.org\/10.1097\/WNF.0000000000000082","journal-title":"Clin Neuropharmacol"},{"key":"9228_CR67","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41531-021-00194-7","volume":"7","author":"B Meira","year":"2021","unstructured":"Meira B, Degos B, Corsetti E, Doulazmi M, Berthelot E, Virbel-Fleischman C, Dodet P, M\u00e9neret A, Mariani L-L, Delorme C et al (2021) Long-term effect of apomorphine infusion in advanced Parkinson\u2019s disease: a real-life study. NPJ Parkinsons Dis 7:50. https:\/\/doi.org\/10.1038\/s41531-021-00194-7","journal-title":"NPJ Parkinsons Dis"},{"key":"9228_CR68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/WNF.0000000000000361","volume":"42","author":"R Bhidayasiri","year":"2019","unstructured":"Bhidayasiri R, Phokaewvarangkul O, Boonpang K, Boonmongkol T, Thongchuem Y, Kantachadvanich N, Garc\u00eda Ruiz PJ (2019) Long-term apomorphine infusion users versus short-term users: an international dual-center analysis of the reasons for discontinuing therapy. Clin Neuropharmacol 42:172\u2013178. https:\/\/doi.org\/10.1097\/WNF.0000000000000361","journal-title":"Clin Neuropharmacol"},{"key":"9228_CR69","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/mdc3.14161","volume":"11","author":"M Aubignat","year":"2024","unstructured":"Aubignat M, Tir M (2024) Continuous subcutaneous foslevodopa-foscarbidopa in Parkinson\u2019s disease: a mini-review of current scope and future outlook. Mov Disord Clin Pract 11:1188\u20131194. https:\/\/doi.org\/10.1002\/mdc3.14161","journal-title":"Mov Disord Clin Pract"},{"key":"9228_CR70","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.parkreldis.2020.09.024","volume":"80","author":"PA LeWitt","year":"2020","unstructured":"LeWitt PA, Chaudhuri KR (2020) Unmet needs in Parkinson disease: motor and non-motor. Parkinsonism Relat Disord 80:S7\u2013S12. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.09.024","journal-title":"Parkinsonism Relat Disord"},{"key":"9228_CR71","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34:2063\u20132073. https:\/\/doi.org\/10.1080\/03007995.2018.1502165","journal-title":"Curr Med Res Opin"},{"key":"9228_CR72","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s00702-023-02686-7","volume":"130","author":"T Henriksen","year":"2023","unstructured":"Henriksen T, Katzenschlager R, Bhidayasiri R, Staines H, Lockhart D, Lees A (2023) Practical use of apomorphine infusion in Parkinson\u2019s disease: lessons from the TOLEDO study and clinical experience. J Neural Transm 130:1475\u20131484. https:\/\/doi.org\/10.1007\/s00702-023-02686-7","journal-title":"J Neural Transm"},{"key":"9228_CR73","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/00207454.2011.620193","volume":"121","author":"JJ Chen","year":"2011","unstructured":"Chen JJ (2011) Pharmacologic safety concerns in Parkinson\u2019s disease: facts and insights. Int J Neurosci 121:45\u201352. https:\/\/doi.org\/10.3109\/00207454.2011.620193","journal-title":"Int J Neurosci"},{"key":"9228_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2022.100174","volume":"8","author":"SH Isaacson","year":"2023","unstructured":"Isaacson SH, Dewey RB, Pahwa R, Kremens DE (2023) How to manage the initiation of apomorphine therapy without antiemetic pretreatment: a review of the literature. Clin Park Relat Disord 8:100174. https:\/\/doi.org\/10.1016\/j.prdoa.2022.100174","journal-title":"Clin Park Relat Disord"},{"key":"9228_CR75","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3233\/JPD-230072","volume":"13","author":"F Stocchi","year":"2023","unstructured":"Stocchi F, Rascol O, Poewe W, Chaudhuri KR, Kassubek J, Lopez Manzanares L, Zhang Y, Bowling A, Pappert E, Wu S (2023) Apomorphine sublingual film compared with subcutaneous apomorphine for OFF episodes in Parkinson\u2019s disease: an open-label, randomized, crossover study. J Parkinsons Dis 13:1329\u20131342. https:\/\/doi.org\/10.3233\/JPD-230072","journal-title":"J Parkinsons Dis"},{"key":"9228_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/6762528","volume":"2016","author":"A-A Poirier","year":"2016","unstructured":"Poirier A-A, Aub\u00e9 B, C\u00f4t\u00e9 M, Morin N, Di Paolo T, Soulet D (2016) Gastrointestinal dysfunctions in Parkinson\u2019s disease: symptoms and treatments. Parkinsons Dis 2016:1\u201323. https:\/\/doi.org\/10.1155\/2016\/6762528","journal-title":"Parkinsons Dis"},{"key":"9228_CR77","unstructured":"Domperidone-containing medicines - referral. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/domperidone-containing-medicines"},{"key":"9228_CR78","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.parkreldis.2016.11.017","volume":"33","author":"R Bhidayasiri","year":"2016","unstructured":"Bhidayasiri R, Garcia Ruiz PJ, Henriksen T (2016) Practical management of adverse events related to apomorphine therapy. Parkinsonism Relat Disord 33:S42\u2013S48. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.017","journal-title":"Parkinsonism Relat Disord"},{"key":"9228_CR79","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1503\/cmaj.1060049","volume":"175","author":"S Khan","year":"2006","unstructured":"Khan S (2006) Clinical utility of the Coombs test. Can Med Assoc J 175:919\u2013919. https:\/\/doi.org\/10.1503\/cmaj.1060049","journal-title":"Can Med Assoc J"},{"key":"9228_CR80","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","volume":"20","author":"F Stocchi","year":"2024","unstructured":"Stocchi F, Bravi D, Emmi A, Antonini A (2024) Parkinson disease therapy: current strategies and future research priorities. Nat Rev Neurol 20:695\u2013707. https:\/\/doi.org\/10.1038\/s41582-024-01034-x","journal-title":"Nat Rev Neurol"}],"updated-by":[{"DOI":"10.1007\/s10072-026-09407-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000}}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09228-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09228-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09228-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:16:16Z","timestamp":1789697776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09228-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9228"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09228-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised. In the original version of the paper, one of the co-authors had passed away before publication, which was unknown to the authors during the final stages of the publication process. As Dr. Manuela Pilleri made a substantial contribution to the work, the authors wish to retain her as a co-author. An article note will be added to the front matter. In addition, the surname of Dr. Manuela Pilleri should be corrected, as one \u201cl\u201d is missing in the published version. The original article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10072-026-09407-4","URL":"https:\/\/doi.org\/10.1007\/s10072-026-09407-4","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CC has received honoraria for speaking at symposia for Ipsen and Teva; NM received honoraria from AbbVie and Bial. The other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"630"}}